5-amino-1mq and cd38 inhibitor synergy nad+ The Pharmacology of CD38/NADase: An emerging target for cancer aging diseases SLC25A51 decouples the mitochondrial NAD+/NADH

SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS driven AML: Cell Metabolism Heavy chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in multiple organs Scientific Reports Inhibition of CD38 by 78c Enhanced NAD+, Alleviated Inflammation, and Decreased Oxidative Stress in Old Murine Macrophages Induced by Oral Pathogens

SKU: 40439757769 · From www.asociacionchamorro.org